HC Wainwright Issues Optimistic Estimate for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Equities researchers at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for Nurix Therapeutics in a note issued to investors on Tuesday, July 1st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.62) per share for the quarter, up from their previous estimate of ($0.74). HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.84) EPS and Q4 2026 earnings at ($0.87) EPS.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC restated a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Leerink Partners started coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective for the company. Stifel Nicolaus lowered their price target on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Finally, Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $30.18.

Nurix Therapeutics Price Performance

NRIX opened at $12.44 on Thursday. Nurix Therapeutics has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The company's 50-day moving average is $11.07 and its 200 day moving average is $14.21. The firm has a market capitalization of $948.43 million, a P/E ratio of -4.44 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 47.49% and a negative net margin of 369.40%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same period in the previous year, the company posted ($0.76) EPS.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the transaction, the chief financial officer owned 33,724 shares in the company, valued at approximately $382,092.92. This represents a 15.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider owned 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,013 shares of company stock valued at $137,096. 7.40% of the stock is owned by insiders.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently modified their holdings of NRIX. Jump Financial LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $1,406,000. Affinity Asset Advisors LLC increased its stake in shares of Nurix Therapeutics by 9.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company's stock valued at $17,711,000 after purchasing an additional 79,684 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $1,026,000. RA Capital Management L.P. purchased a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $25,120,000. Finally, Norges Bank bought a new stake in shares of Nurix Therapeutics in the 4th quarter worth approximately $6,006,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.